June 19, 2026 Why Some Treatments Are Not Covered by HMOs

For many Filipinos, the most difficult moment in using an HMO does not begin at the hospital cashier or the clinic reception desk. It begins with a sentence that feels both technical and personal: “This treatment is not covered.” 

To the patient, the issue is immediate. A doctor has recommended a test, a procedure, a medicine, or a course of treatment. The need feels urgent. The cost may be substantial. The expectation is simple: if one has an HMO, healthcare should be easier to access.

To the HMO, the issue is also immediate, but in a different way. Every benefit promised to one member must be funded by the collective contributions of many members. Every inclusion affects pricing. Every exception affects trust. Every uncontrolled cost eventually returns as a higher premium for employers, SMEs, families, and individuals. 

This tension sits at the center of managed healthcare. HMOs exist to expand access to healthcare by pooling risk, negotiating with hospitals and clinics, organizing provider networks, and making care more predictable. But they are not unlimited health funds. They operate within actuarial, contractual, regulatory, and economic boundaries. Understanding why some treatments are not covered is essential not only for members, but also for HR leaders, finance heads, healthcare providers, regulators, and policymakers trying to manage medical inflation while protecting workforce wellbeing. 

The simplest explanation is affordability. The more complete a health plan becomes, the more expensive it becomes. A plan that covers every treatment, every medicine, every pre-existing condition, every experimental therapy, every elective procedure, and every high-cost intervention without limit would be ideal from the perspective of access. It would also be unaffordable for many employers and individuals in the Philippines. 

This is why exclusions and limitations exist. They are not merely technical fine print. Properly designed, they are tools for keeping health plans financially viable, premiums manageable, and benefits available to the wider population. Poorly designed or poorly explained, however, they can create confusion, frustration, and distrust. 

The actuarial logic is straightforward. HMOs price plans based on expected healthcare utilization, claims experience, demographics, medical cost trends, provider behavior, benefit design, and administrative costs. If a treatment is highly predictable, extremely expensive, already existing before enrolment, elective rather than medically necessary, experimental, or difficult to price due to limited evidence, it may be excluded, capped, subject to waiting periods, or covered only under specific conditions. 

This is not unique to the Philippines. Health financing systems around the world face the same challenge: how to allocate limited resources across a population with unlimited possible health needs. The World Health Organization describes health financing as a core function of health systems because it determines how funds are raised, pooled, and used to purchase services. The policy objective is not simply to spend more, but to design financing arrangements that improve access, quality, and financial protection. 

In private managed healthcare, this means choices must be made. Covering one benefit without adjusting premiums, limits, underwriting rules, or provider controls may weaken the plan’s ability to pay for other benefits. If high-cost claims rise faster than contributions, the result is eventually felt by everyone through higher renewal rates, narrower benefits, stricter underwriting, or reduced access. 

This is particularly important in 2026 because employer-sponsored health plans across Asia are under pressure from rising medical costs. Mercer Marsh Benefits reported that employer-provided health plans in Asia are facing a projected medical trend rate of 12.5 percent in 2026, close to six times the inflation rate in the region. WTW’s 2026 Global Medical Trends Survey similarly reported that medical inflation remains highest in Asia Pacific, with cost increases expected to reach 14 percent in 2026. 

These figures matter for Philippine employers because HMOs are not a discretionary perk for many leading companies. They are part of the employee value proposition. For large employers, BPOs, shared services firms, banks, manufacturers, retailers, and professional services firms, health benefits help attract and retain talent. For SMEs and small and medium enterprises, affordable health coverage can be the difference between offering meaningful employee benefits and offering none at all. 

When medical inflation rises, the question is no longer whether companies want generous benefits. Most do. The question is how much generosity can be sustained without making health insurance unaffordable. HR teams want broader coverage. CFOs need cost discipline. Employees want immediate access to hospitals, clinics, doctors, and medicines. HMOs must balance all three. 

This is why coverage exclusions usually fall into several broad categories. 

Some treatments are excluded because they are elective rather than medically necessary. Cosmetic procedures, non-essential enhancements, and treatments primarily intended for aesthetic purposes are often outside standard HMO coverage. This is not because they have no value to the individual, but because they are not usually considered part of medically necessary risk protection. 

Some treatments are limited because they relate to pre-existing conditions. In the Philippine HMO context, the Insurance Commission has recognized pre-existing conditions as injuries, illnesses, or diseases that affect a member before the effectivity of a health maintenance contract. The regulatory logic is linked to adverse selection, or the tendency of people with known higher health risks to seek coverage when they expect to use it. If pre-existing conditions were always covered immediately and without pricing adjustments, premiums for the wider pool would rise. 

Some treatments are excluded or restricted because evidence remains uncertain. Experimental therapies, unproven procedures, off-label interventions, or technologies not yet supported by sufficient clinical evidence are difficult to price and difficult to standardize. A healthcare provider may believe a treatment is promising, but a managed healthcare plan must ask a different question: should this treatment be funded by the pooled contributions of all members at this time, and under what clinical criteria? 

Some treatments are excluded because they are covered by another financing mechanism or require specialized insurance structures. Catastrophic illnesses, long-term rehabilitation, highly specialized cancer protocols, organ transplants, fertility treatments, psychiatric confinement, advanced biologics, or rare disease therapies may require separate riders, higher benefit limits, special underwriting, or different forms of health insurance. The issue is not whether these needs are real. They are. The issue is whether a standard HMO plan was priced to absorb them. 

Some treatments are restricted because of provider network arrangements. HMOs build a provider network of hospitals, clinics, physicians, laboratories, and other healthcare providers. A big network improves healthcare access, but it also requires contracting, credentialing, pricing discipline, claims monitoring, and service-level management. A treatment may be covered in principle but not available through every hospital or clinic in the network. In other cases, an HMO may require pre-authorization to confirm medical necessity and manage cost exposure. 

This is where customer service becomes part of the healthcare promise. A technically sound exclusion can still become a poor member experience if it is explained late, vaguely, or defensively. Members rarely object only to the existence of rules. They object to rules they did not understand, could not find, or discovered only when they were already seeking care. 

For trusted HMOs in the Philippines, the challenge is therefore not merely actuarial. It is communicative. Benefit design must be written in language that ordinary members can understand. HR teams must receive enough guidance to explain coverage to employees. Hospitals and clinics must be aligned on authorization processes. Customer service teams must be trained not only to deny or approve, but to explain alternatives. 

This is also where preventive care becomes strategically important. The most sustainable claim is often the claim that could have been avoided through earlier detection, chronic disease management, telemedicine, lifestyle support, or better primary care. For employers, workplace health programs are no longer soft initiatives. They are cost-management tools. A workforce with unmanaged hypertension, diabetes, sleep issues, mental health concerns, or delayed consultations will eventually generate higher medical costs. 

In this context, digital health services can help shift the model from reactive care to earlier intervention. For example, iCare’s Telemed7, which allows members to consult doctors remotely, illustrates how an HMO can use technology to improve access to medical advice before a condition escalates into a more expensive hospital-based encounter. iCare also publicly states that it maintains a network of more than 2,000 hospitals and clinics and more than 50,000 accredited doctors and medical practitioners nationwide. These capabilities are relevant not because they eliminate exclusions, but because they show how managed healthcare can combine affordability, access, and service design. 

The broader lesson is that coverage limits should not be viewed in isolation. A plan with fewer exclusions but poor access may still disappoint members. A plan with a large provider network but unclear benefit rules may still create friction. A plan with affordable premiums but weak preventive care may become expensive over time. The best HMO design is not the one that promises everything. It is the one that aligns benefits, pricing, provider access, claims discipline, preventive care, and member communication in a way that can be sustained. 

The Philippine regulatory context also matters. HMOs are regulated by the Insurance Commission under the framework established after Executive Order No. 192, Series of 2015 transferred jurisdiction over HMOs to the Commission. The Commission has issued rules covering HMO contracts, pre-existing conditions, free-look periods, financial reporting, actuarial valuation, and minimum capitalization. These rules reflect an important policy reality: an HMO must be consumer-facing, but it must also remain financially sound. 

That is why sustainability is not an abstract corporate concern. If an HMO underprices risk or covers benefits without adequate reserves, members may initially enjoy low premiums or broad promises. Over time, however, the system becomes fragile. Claims may outpace collections. Provider payments may become strained. Renewal pricing may spike. The very affordability that attracted members can become unsustainable. 

For employers, this means the annual HMO discussion should mature beyond a simple comparison of premiums. HR and finance leaders should ask how benefits are priced, which exclusions matter most to their workforce, how pre-existing conditions are treated, how claims trends are monitored, how the provider network is managed, and what preventive health programs can reduce long-term utilization. For large employers, this is a workforce strategy issue. For SMEs, it is a financial resilience issue. For top employer brands, it is part of employee experience. 

For members, the practical lesson is equally important. An HMO card is not a blank cheque. It is a contract for specified healthcare services under defined conditions. Members should understand their annual benefit limit, exclusions, waiting periods, pre-authorization requirements, emergency provisions, reimbursement rules, and accredited provider network.  

They should ask questions before they need urgent care, not only when a claim is denied. 

For healthcare providers, the challenge is partnership. Hospitals, clinics, and doctors have legitimate concerns about clinical judgment, reimbursement rates, administrative burden, and patient expectations. HMOs have legitimate concerns about overutilization, inconsistent billing, unnecessary procedures, and cost escalation. A healthier system requires less adversarial engagement and more data-driven collaboration around quality, outcomes, access, and cost. 

For policymakers, the larger question is how private HMOs fit within the country’s broader health financing architecture. The Philippines continues to pursue universal health care while households, employers, PhilHealth, private insurers, HMOs, and out-of-pocket payments all play roles in financing care. Fragmentation remains a policy concern. Better coordination between public and private financing can help reduce gaps, duplication, and confusion. 

The difficult truth is that no health financing system can cover everything for everyone at no cost. The more serious policy question is how limits are set, who bears the cost, how transparent the rules are, and whether the system protects people from the most financially damaging health events while encouraging earlier and better care. 

In the end, exclusions are not necessarily a sign that an HMO is failing. They are a sign that healthcare has to be financed, priced, managed, and governed. What matters is whether those exclusions are reasonable, clearly communicated, regulatorily compliant, actuarially justified, and balanced by meaningful access to covered care. 

As medical inflation continues to pressure employers and households, the future of managed healthcare in the Philippines will depend on a more honest conversation. Affordable health coverage cannot mean unlimited coverage at unsustainable prices. Sustainable coverage cannot mean opaque exclusions that surprise members at the point of care. The most trusted HMOs will be those that can hold both truths at once: healthcare must be compassionate enough to serve people in moments of need, and disciplined enough to remain available when the next member needs it too. 

Sources and References 

Aon. (2025). 2026 Global Medical Trend Rates Report.
https://www.aon.com/en/insights/reports/global-medical-trend-rates-report 

Insurance Commission of the Philippines. Circular Letter No. 2017-19: Guidelines on the Standard Provisions in Health Maintenance Organization Agreements.
https://www.insurance.gov.ph/circular-letters/ 

Insurance Commission of the Philippines. Circular Letter No. 2018-66: Free-Look Period on Health Maintenance Contracts.
https://www.insurance.gov.ph/circular-letters/ 

Insurance Commission of the Philippines. Circular Letter No. 2025-11: Revised Minimum Capitalization, Financial Capacity and Other Regulatory Requirements for HMOs.
https://www.insurance.gov.ph/circular-letters/ 

 Insurance Commission of the Philippines. HMO Industry Performance Reports.
https://www.insurance.gov.ph/statistics/ 

iCare HMO Philippines. Accredited Hospitals and Clinics.
https://icare.com.ph/accredited-hospitals-clinics/ 

iCare HMO Philippines. Find a Doctor.
https://icare.com.ph/find-a-doctor/ 

iCare HMO Philippines. Telemed7.
https://icare.com.ph/  

Mercer Marsh Benefits. (2025). Asia Health Trends 2026.
https://www.mercer.com/en-ph/insights/total-rewards/employee-benefits/ 

Paterno, R. P. P. (2023). How Do We Finance Universal Health Care in the Philippines? University of the Philippines Center for Integrative and Development Studies.
https://cids.up.edu.ph/wp-content/uploads/2023/02/How-do-we-finance-Universal-Helath-Care-in-the-Philippines-Ramon-Pedro-P.-Paterno.pdf  

Bredenkamp, C., et al. (2015). Universal Health Coverage in the Philippines. World Bank.
https://openknowledge.worldbank.org/entities/publication/60211af9-177e-5452-a250-225c88a48d0b  

Department of Health. (2023). Health Care Financing Strategy of the Philippines 2023-2028: Towards Universal Health Care.
https://p4h.world/en/documents/health-care-financing-strategy-of-the-philippines-2023-2028-towards-universal-health-care/  

Willis Towers Watson (WTW). (2025). 2026 Global Medical Trends Survey.
https://www.wtwco.com/en-ph/insights/2026-global-medical-trends-survey 

World Health Organization. Health Financing.
https://www.who.int/health-topics/health-financing  

 World Health Organization. (2025). Universal Health Coverage (Fact Sheet).
https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-%28uhc%29